1. American Diabetes Association. Standards of medical care in diabetes : 2013. Diabetes Care 2013; 36 (suppl 1) : S11–66.
2. HAS. Recommandation sur la stratégie du contrôle glycémique du diabète de type 2.
3. Roussel R, Travert F, Pasquet B et al and the Reduction of Atherothrombosis for Continued Health (REACH) registry investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892.99.
4. Boussageon R, Supper I, Bejan-Angoulvant T et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012;9(4):e1001204.
5. Protti A, Lecchi A, Fortunato F et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care 2012;16: R180.
6. Ekström N, Schiöler L, Svensson AM et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012; 2: e001076.
Mise au point
Prise en charge de la goutte en 2025
Mise au point
Le prurit
Mise au point
Les infiltrations en médecine générale
Mise au point
Diagnostic de la maladie d’Alzheimer en 2025